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Summary
PRINCIPLES: We aimed to evaluate the efficacy of, and
treatment satisfaction with, insulin glargine administered
with SoloSTAR® or ClikSTAR® pens in patients with type
2 diabetes mellitus managed by primary care physicians in
Switzerland.
METHODS: A total of 327 patients with inadequately con-
trolled type 2 diabetes were enrolled by 72 physicians in
this prospective observational study, which aimed to eval-
uate the efficacy of a 6-month course of insulin glargine
therapy measured as development of glycaemic control
(glycosylated haemoglobin [HbA1c] and fasting plasma
glucose [FPG]) and weight change. We also assessed pref-
erence for reusable or disposable pens, and treatment satis-
faction.
RESULTS: After 6 months, the mean daily dose of insulin
glargine was 27.7 ± 14.3 U, and dose titration was com-
pleted in 228 (72.4%) patients. Mean HbA1c decreased
from 8.9% ± 1.6% (n = 327) to 7.3% ± 1.0% (n = 315)
(p <0.0001), and 138 (43.8%) patients achieved an HbA1c
≤7.0%. Mean FPG decreased from 10.9 ± 4.5 to 7.3 ± 1.8
mmol/l (p <0.0001). Mean body weight did not change
(85.4 ± 17.2 kg vs 85.0 ± 16.5 kg; p = 0.11). Patients’
preference was in favour of the disposable SoloStar® pen
(80%), as compared with the reusable ClickStar® pen
(20%). Overall, 92.6% of physicians and 96.3% of patients
were satisfied or very satisfied with the insulin glargine
therapy.
CONCLUSIONS: In patients with type 2 diabetes insulin
glargine administered by SoloSTAR® or ClikSTAR® pens,
education on insulin injection and on self-management of
diabetes was associated with clinically meaningful im-
provements in HbA1c and FPG without a mean collective
weight gain. The vast majority of both patients and primary
care physicians were satisfied with the treatment intensific-
ation.
Key words: type 2 diabetes mellitus; insulin glargine;
ClikSTAR®; SoloSTAR®; HbA1c; FPG; patient satisfaction;
patient empowerment; primary care
Introduction
Diabetes mellitus represents a fast growing worldwide epi-
demic: In 2010, an estimated 285 million people were af-
fected by type 2 diabetes. The projected numbers for 2030
reach 439 million people, owing to a marked increase of
prevalence in young adults and adolescents and, in certain
regions such as Africa, the Middle East and Asia [1]. In
Switzerland, the prevalence of type 2 diabetes is estimated
at 5.7–7% of the overall population, corresponding to ap-
proximately 500,000 people [2]. In patients with type 2 dia-
betes, hyperglycaemia enhances the risk of vascular dis-
ease, acute myocardial infarction, stroke, lower limb am-
putation and microvascular complications [2–6]. Real-life
data from a survey in 157,000 American patients with type
2 diabetes, however, indicate that over two-thirds of the pa-
tients have HbA1c concentrations >6.5%, which may cause
considerable long-term complications and healthcare costs
[7].
Once life-style intervention and one or more oral antidia-
betic drugs (OADs) become ineffective to lower HbA1c
to target levels, the addition of basal insulin, particularly
in patients with high fasting blood glucose (FBG) levels,
is highly recommended [8]. Good glycaemic control over
time is required to reduce the risk of diabetes-associated
complications [8, 10]. Type 2 diabetes guidelines and al-
gorithms that highlight the importance of basal insulin for
the management of the disease have been published in re-
cent years jointly by the American Diabetes Association
(ADA) and the European Association for the Study of Dia-
betes (EASD). Based on the above mentioned guidelines,
the SSED (Swiss Society of Endocrinology and Diabetes)
has published its own recommendations [12, 13]. Whereas
the addition of basal insulin to existing OAD treatment was
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recommended in patients with HbA1c levels above 7% in
the former SSED guidelines from 2009 [12], individual tar-
get levels between 6% and 8% are recommended in the
new SSED guidelines published in 2013 [13].
Clinical trials demonstrated the benefit of insulin glargine,
a basal-insulin analogue [14], to achieve HbA1c levels of
<7% in patients with uncontrolled type 2 diabetes mellitus
[8, 15–27]. Optimisation and long-term maintenance of
glycaemic control with insulin glargine was confirmed in
large cohorts of patients with type 2 diabetes [10, 22, 23],
and advantages of insulin glargine compared with other in-
sulins and antidiabetic medication were described in sever-
al studies [8, 15, 17, 19, 20, 24, 25].
Patients requiring insulin are challenged by complex inter-
ventions for their disease. They have to manage multiple
blood glucose measurements and to balance carbohydrate
intake and daily insulin injections [8]. Failure to initiate or
noncompliance with insulin treatment regimens represents
a common and critical issue for reaching therapeutic goals.
Insulin use by patients is often limited by factors such as
fear of injection and hypoglycaemia, but could also be also
related to the injection device itself. Therefore, easy-to-use
devices may positively influence physicians’ insulin pre-
scribing habits and patient compliance [8]. The conveni-
ent and simple handling of SoloSTAR® and ClikSTAR®
represents a big step forward towards easy self-manage-
ment of diabetes and lead to increased treatment adherence
and higher patient satisfaction [8, 26]. Thus, administration
of insulin glargine with SoloSTAR® and ClikSTAR® pens
contributes to the optimisation of diabetes treatment [27].
In addition, education on self-management of diabetes re-
flects a further important aspect of the current patient-
centred approach. The later focuses on the patient’s needs
and abilities with the aim to improve their knowledge and
skills, thus enabling better self-management of treatment
regimens and life-style interventions [8, 28, 29].
The aim of the present study was to evaluate the efficacy
of a 6-month course of insulin glargine therapy measured
as development of the glycaemic control (HbA1c and FPG)
and weight change. We also assessed, whether patients will
choose a reusable or a disposable pen, and the treatment
satisfaction with SoloSTAR® (disposable pre-filled insulin
pen) and ClikSTAR® (reusable insulin pen for 3 ml in-
sulin cartridges) in patients with type 2 diabetes mellitus
managed by primary care physicians in various regions of
Switzerland.
Patients and methods
Patients
Seventy-two physicians in primary medical care across
Switzerland participated in the present prospective obser-
vational study conducted between November 2009 and
September 2011. All patients with poorly controlled type
2 diabetes mellitus despite prior treatment with OAD(s) or
insulin were eligible to participate. Inclusion criteria were
age >18 years, HbA1c >7%, and the patient’s informed
consent. There were no exclusion criteria. The reasons for
nonparticipation in the study were not systematically cap-
tured. In accordance with local regulations, informed con-
sent was provided by the participating patients. Treatment
with insulin glargine (Lantus®, Sanofi-Aventis (Schweiz)
AG, Vernier, Switzerland) and pens for subcutaneous ad-
ministration (SoloSTAR® and ClikSTAR®, Sanofi-Aventis
(Schweiz) AG, Vernier, Switzerland) was prescribed as a
part of routine medical care and used according to the
product information [30]. Participating physicians were en-
couraged to provide education on the appropriate adminis-
tration of insulin glargine, the use of pens and concomit-
ant life-style interventions to enable patients to self-man-
age their disease and to assist patients to choose which
pen to use (the disposable (SoloSTAR) or the reuseable
(ClikSTAR) pen). Information on self-management of dia-
betes was at the discretion of the treating physician. The
first patient was included in the observation study on 1
November 2009 and the last patient was included on 31
March 2011. With the exception of the first visit and a visit
at after 6 months of insulin glargine treatment, there was
no systematic monitoring of treatment with insulin glargine
other than routine clinical visits as ordered by the particip-
ating physicians. The study was approved by an Independ-
ent Ethics Committee according to local regulations.
Outcome measures
Patient demographics, vital signs (systolic and diastolic
blood pressure) and lipids (triglycerides, high and low
density lipoprotein cholesterol), medical history and com-
plications of diabetes, concomitant diseases, previous treat-
ment of diabetes, and recommended dose titration of in-
sulin glargine were recorded at the baseline (BL) visit.
Initial dose, titration scheme and actual dose of insulin
glargine were recorded at the follow-up (FU) routine med-
ical care visit after 6 months. The effectiveness parameters
(HbA1c and FPG) were recorded at the BL and FU visits.
There was no reference laboratory used for the biochemical
analysis, but rather the laboratory in the doctor’s office or
an external laboratory used by the doctor’s office. Safety
events were reported directly to the Swissmedic Pharma-
covigilance centres according to national regulatory re-
quirements. Satisfaction was evaluated using the four-point
Likert scale (very dissatisfied, dissatisfied, satisfied, very
satisfied) by interview of the patients and by questionnaire
for the physicians. The results were entered into the case
report form (CRF) directly by participating physicians.
Statistical analysis
All patients with data records at BL and FU visits were
included in the intention-to-treat (ITT) analysis (n = 315),
and all patients compliant with the eligibility criteria and
appropriate visit interval were considered for the per-pro-
tocol (PP) analysis (n = 300). Baseline characteristics, an-
tidiabetic treatment and safety were assessed in the ITT
population. Efficacy (HbA1c and FPG) and treatment sat-
isfaction were analysed using the PP population. Continu-
ous variables with a normal distribution were described as
means with standard deviations (SDs), and group compar-
isons were performed with the independent or paired t-
test; continuous variables with a skewed distribution were
presented as median values. Changes in HbA1c between
different titration groups was analysed by using multiple
linear regression, controlled for baseline HbA1c with and
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Bonferroni-correction of the significance level if more than
two groups were compared. Discrete variables were
presented as frequencies and percentages, and group com-
parisons were performed using the chi-square test. All re-
ported p-values are two-sided. Patient data were entered
into the CRF directly by the treating physicians. Data man-
agement and analysis was performed by Ulrich Kreuter
Statistik GmbH, Schwarzenburg. Data were analysed using
SAS 9.1, SAS Institute Inc., SAS Campus Drive, Cary,
North Carolina 27513, USA.
Results
Patient disposition
Out of 327 patients included, 12 (3.7%) patients did not re-
turn to the FU visit and were considered as lost to follow-
up. In 9 (2.8%) out of 315 patients (ITT) early termination
due to intermittent disease, patient’s decision, noncompli-
ance or short visit interval (<8 weeks) was recorded. Fur-
thermore, 6 (1.9%) patients with HbA1c <7.0% at the BL
visit (representing a protocol violation) were excluded
from the PP population (300 patients). The mean number
of patients enrolled per centre was 4.4 (median 4). With
regard to the distribution across regions, all major areas
and language regions of Switzerland were represented in
Table 1: Demographics, blood pressure, lipids, medical history (mean ± SD) and diabetic complications (No. and %) at the baseline visit (intention to treat population, n =
315).
Demographics No. Mean Standard deviation
Gender: Female 147 (46.7%)
Male 168 (53.3%)
Age (years) 315 62.2 11.4
Weight (kg) 315 85.4 17.2
Height (cm) 315 161.1 16.3
Body mass index (kg/m2) 315 29.7 5.4
Smoking (% of study population) 314 85 (27.1)
Blood pressure
Systolic blood pressure (mm Hg) 309 139.4 14.2
Diastolic blood pressure (mm Hg) 309 83.1 9.4
Lipids
Triglycerides (µmol/l) 215 2.52 1.36
High density lipoproteins (µmol/l) 210 1.18 0.62
Low density lipoproteins (µmol/l) 199 3.23 1.13
Medical history
Diabetes duration (years) 7.26 6.28
Diabetic complications (micro- and macro-vascular) No. %
Retinopathy 315 38 12.1
Nephropathy 315 67 21.3
Known microalbuminuria 315 106 33.7
Neuropathy 315 66 21.0
Coronary heart disease 315 82 26.0
--- Myocardial infarction 82 29 35.4
Stroke 315 5 1.6
Peripheral arterial occlusive disease 315 22 7.0
Table 2: Use of antidiabetic drugs prior to enrolment and reasons to change the antidiabetic treatment indicated at baseline visit. Figures represent the number and
percent of patients in the intention to treat population (n = 315).
(a) Previous treatments
Oral antidiabetics 282 89.5% Insulin 47 14.9%
Metformin 259 82.2% Short-acting 11 3.5%
Sulfonylurea 126 40.0% Intermediate-acting 19 6.3%
Glitazones 100 31.7% Long-acting 30 9.5%
Glinides 27 8.6%
GLP-1 agonists 3 1.0%
DPP-4 Inhibitors 53 16.8%
(b) Reasons to change treatment
Oral antidiabetics 282 89.5% Insulin 47 14.9%
Not on target 230 81.6% Not on target 35 74.5%
Hypoglycaemia 5 1.8% Hypoglycaemia 9 19.1%
Skin irritation 9 3.2% Skin irritation 2 4.3%
Other adverse events 21 7.4% Other adverse events 1 2.1%
Dissatisfaction 30 10.6% Dissatisfaction 1 2.1%
Pen 1 2.1%
DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1
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this study: 244 (77.5%) patients were included from the
German-speaking, 39 (12.4%) from the French-speaking,
and 32 (10.1%) from the Italian-speaking parts of Switzer-
land.
Demographics and disease characteristics
Baseline characteristics are presented in table 1. The mean
age (±SD) was 62.2 ± 11.4 years (range 17‒92 years) and
Figure 1
Assessment of efficacy (blood glucose control) by physician,
evaluation of satisfaction with therapy and device by patients:
Proportions of physicians and patients who were “very satisfied”,
“satisfied”, “dissatisfied” or “very dissatisfied” (per protocol
population, n = 300).
Figure 2
Weight change in relation to improvement of HbA1c. Correlation of
weight change and change in HbA1c, p = 0.01.
Figure 3
Improvement of HbA1c with the different titration schemes.
A) Physician = titration managed by physician (n = 221), patient =
titration managed by patient (n = 91); p = 0.049, adjusted for
baseline HbA1c.
B) Improvement of HbA1c in the different titration groups. 1 =
change of 2 U every 3 days (n = 58), 2 = weekly adjustment (n =
230), 2 = other titration scheme (n = 27), p = not significant,
adjusted for baseline HbA1c.
C) Titration end not reached (n = 87), Titration end reached (n =
228); p <0.001, adjusted for baseline HbA1c.
the mean body mass index (BMI) was 29.7 ± 5.4 (range
17‒56). The mean systolic and diastolic blood pressures
were 139 ± 14 and 83 ± 9 mm Hg, respectively, the mean
concentrations of triglycerides (TG), high density lipopro-
tein (HDL) and low density lipoprotein (LDL) cholesterol
were 2.52 ± 1.36 µmol/l, 1.18 ± 0.62 µmol/l and 3.23 ±
1.13 µmol/l, respectively. The average time from the dia-
gnosis of diabetes was 7.3 ± 6.3 years and the following
diabetic complications were reported at baseline: microal-
buminuria (33.7%), coronary heart disease (26.0%) includ-
ing myocardial infarction in 9.2%), peripheral arterial oc-
clusive disease (7.0%), stroke (1.6%), neuropathy (21.3%),
nephropathy (21.0%) and retinopathy (12.1%). In total,
27.0% of patients were smokers.
Treatments
At the BL visit, 282 (89.9%) patients were treated with one
or more OADs and 47 (14.9%) patients with insulin. The
proportions of patients using metformin, sulfonylureas, gl-
itazones, DPP-4–inhibitors, glinides, GLP-1–agonists and
any insulin are shown in table 2a. Sulfonylureas were pre-
scribed initially to 126 (40.0%) patients and at 6 months to
87 patients (27.6%), of whom 5 had a dose reduction, and 3
were additionally started on sulfonylureas. The reasons to
change OAD or insulin treatment are summarised in table
2b.
Titration of insulin glargine and therapeutic education
of patients
The initial dose of insulin glargine was either 10 U (61.9%)
or 0.2 U/kg (26.7%) according to protocol, and in 11.4%
of the patients the initial insulin dose was higher (mean ±
SD 16.5 ± 8.6 U), mostly in patients that were previously
on insulin treatment. The titration of glargine was managed
by physicians (71.1%) or by patients (28.9%), either with
weekly adjustment (73.0%) or a change of 2 U every 3
days (18.4%), and was completed at the FU visit after 6
months in 72.4% of the patients. These patients had a lower
HbA1c level as compared with the patients not finishing
titration (fig. 3C). The insulin dose was adjusted accord-
ing to two established algorithms, which could be chosen
by the physician: Once weekly, based on the FPG values
during the two previous days (table 3) or, more simply, an
increase of 2 U every three days, if the FBG was not on
target. The titration scheme was not associated with a dif-
ferent HbA1c (fig. 3B). However, titration by the physician
resulted in a slightly higher HbA1c improvement as com-
pared with titration by the patient (fig. 3A). The mean daily
dose of insulin glargine was 27.7 ± 14.3 U and the mean
duration of treatment was 178 ± 56 days. ClickSTAR® and
SoloSTAR® pens were used in 20% and 80% of patients,
respectively. The proportion of patients treated with OADs
remained stable during the study period (89.9% at BL vs
88.9% at the FU visit).
At the BL visit, education on self-management of diabetes
was carried out in 303 (96.2%) patients, mainly by phys-
icians (95.4%), diabetes experts (37.3%), diet experts
(28.1%) and psychotherapists (1.0%). A similar pattern of
educational support was recorded at the FU visit.
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Efficacy
In the ITT population, the mean HbA1c decreased from
8.9% ± 1.6% at the BL visit to 7.3% ± 1.0% at the FU
visit, resulting in a significant difference of –1.6% ± 1.7%
(p <0.0001). The mean FPG decreased from 10.8 ± 4.4
mmol/l at the BL visit to 7.3 ± 1.8 mmol/l at the FU visit
with a significant change of –3.6 ± 4.5 mmol/l (p <0.0001).
The proportion of patients with an HbA1c level ≤7.0% in-
creased from 4.8% to 43.8% (p <0.0001), and the propor-
tion of patients with FPG ≤7.0 mmol/l increased from 9.6%
to 50.3% (p <0.0001). The mean body weight remained
stable during the study period (85.4 ± 17.2 kg at the BL vs
85.0 ± 16.5 kg at the FU visit; p = 0.11).
In the PP population, the mean HbA1c decreased from 8.9%
± 1.6% at the BL visit to 7.3% ± 1.0% at the FU visit result-
ing in a significant difference of –1.6% ± 1.7% (p <0.0001)
(table 4). At the BL visit, the mean HbA1c correlated sig-
nificantly (p = 0.022) with age group, being the highest
(9.5% ± 1.8%) in patients ≤49 years and the lowest (8.6% ±
1.4%) in patients ≥ 70 years. The differences from the BL
visit to the FU visit showed a trend (p = 0.19) to greatest
prominence in the youngest compared with the oldest age,
resulting in a similar mean HbA1c at the FU visit (table 4c).
The mean FPG decreased from 10.9 ± 4.5 mmol/l at the
BL visit to 7.3 ± 1.8 mmol/l at the FU visit with a signific-
ant change of –3.6 ± 4.6 mmol/l (p <0.0001). The propor-
tion of patients with an HbA1c level ≤7.0% increased from
3.0% to 45.3% (p <0.0001), and the proportion of patients
with FPG ≤7.0 mmol/l increased from 9.2% to 50.7% (p
<0.0001). The mean body weight remained stable during
the study period (85.4 ± 17.2 kg at BL vs 85.0 ± 16.5 kg at
the FU visit; p = 0.11) (fig. 2).
Tolerability
At the beginning of this prospective observational study,
participating physicians were informed about their obliga-
tion to report spontaneous serious safety events directly to
the Swissmedic Pharmacovigilance centres using the spe-
cific Swissmedic form. Hypoglycaemia was reported in
one (0.3%) patient in the comment section of the CRF.
Otherwise, no adverse drug reactions have been documen-
ted.
Outcomes assessments and patient satisfaction
Overall, 92.7% of treating physicians and 96.3% of patients
were satisfied or very satisfied with the insulin glargine
therapy (fig. 1); 45.3% physicians and 50.3% patients were
satisfied whilst 47.3% physicians and 46.0% patients were
very satisfied with the insulin glargine therapy. Similarly,
99.0% of patients were satisfied or very satisfied with the
use of SoloSTAR® or ClikSTAR® pens; 46.3% patients
were satisfied and 52.7% were very satisfied with the So-
loSTAR® or ClikSTAR® pens. The patients’ preference
was in favour for the disposable SoloSTAR® pen (80%), as
compared with the reusable ClickSTAR® pen (20%).
Discussion
In this prospective, observational study conducted in a
large cohort of patients with previously uncontrolled type
Table 4: (a) Mean (standard deviation; SD) HbA1c and fasting blood glucose (FPG) at baseline (BL) and follow-up (FU) visits. The paired differences in mean (SD) HbA1c
and FPG from BL visit to FU visit after 6 months. The reported p-values were calculated using the paired t-test. (b) Number and frequency of patients allocated to defined
groups of HbA1c and FPG levels at BL and FU visits. (c) Mean (SD) HbA1c by age group at BL and FU visits and mean change from BL visit to FU visit after 6 months.
Figures represent the number and percent of patients of the per protocol population (n = 300).
(a) Mean values Visit No. Mean SD 95% confidence
interval
p-value
BL 300 8.9 1.6 8.7–9.1HbA1c (%)
FU 300 7.3 1.0 7.1–7.4
Difference FU ‒ BL 300 -1.6 1.7 1.8–1.5 <0.0001
BL 295* 10.9 4.5 10.4–11.4FPG (mmol/l)
FU 294* 7.3 1.8 7.0–7.5
Difference FU – BL 293* –3.7 4.6 4.2–3.1 <0.0001
(b) Distribution Visit No. ≤6.5% ≤7.0% ≤8.0% >8.0%
BL 300 0 (0.0%) 9 (3.0%) 97 (32.3%) 194 (64.7%)
FU 300 63 (21.0%) 73 (24.3%) 122 (40.7%) 42 (14.0%)
HbA1c (%)
≤5.5 ≤7.0 ≤8.0 >8.0
BL 295* 4 (1.4%) 23 (7.8%) 38 (12.9%) 230 (78.0%)FPG (mmol/l)
FU 294* 37 (12.6%) 112 (38.1%) 78 (26.5%) 67 (22.8%)
HbA1c by age group Visit Age group No. Mean SD p-value
BL ≤49 35 9.5 1.8
50–59 77 9.1 1.9
60–69 108 8.8 1.4
HbA1c (%)
≥70 80 8.6 1.4 0.022
FU ≤49 35 7.5 0.9
50–59 77 7.2 0.9
60–69 108 7.2 0.8
HbA1c (%)
≥70 80 7.2 1.1 0.49
FU – BL ≤49 35 –2.1 1.9
50–59 77 –1.8 2.1
60–69 108 –1.6 1.3
HbA1c (%)
≥70 80 –1.4 1.6 0.19
* Lower numbers are due to missing values.
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2 diabetes mellitus in a primary care setting, a 6-month
course of insulin glargine administered with SoloSTAR®
or ClikSTAR® pens, and education on insulin injection
with these devices and on self-management of diabetes
was associated with a clinically relevant improvement in
glycaemic control (fasting plasma glucose and HbA1c)
without an increase in mean body weight of the entire co-
hort. The vast majority of patients and physicians were sat-
isfied with the treatment.
Comparison of randomised studies with real world
results of this observational study
Our study presents “real world” results of a patient-centred
approach encompassing treatment with insulin glargine us-
ing ClickSTAR® and SoloSTAR® pens and education by
physicians to enable patients to self-manage the disease.
Initiation of insulin glargine treatment and dose titration
was managed in 73% of patients according the scheme of
Riddle et al. [15] and in 18% of patients following the
scheme of the ADA/EASD [11]. Interestingly, self-man-
agement of dose titration was reported more frequently in
the present study than in a previous study [22] conducted
between 2005 and 2007 in Switzerland (29% vs 17%). This
observation mirrors a trend in the medical community to
increasingly promote therapeutic education and self-em-
powerment of patients. However, our results demonstrate
that titration by the physician resulted in a slightly higher
improvement of HbA1c, in contrast to the choice of titration
scheme, which did not influence the outcome. The titration
was completed after 6 months in 72% of patients with a
mean insulin glargine dose of 27.7 ± 14.3 U, corresponding
to a mean of 0.32 ± 0.17 U/kg. This resembles the lower
range of insulin replacement in patients with initial treat-
ment intensification. The patients who completed the titra-
tion scheme had a significantly lower HbA1c level.
In agreement with results from large clinical trials [15, 17,
20, 21], treatment with insulin glargine during a period of
24 weeks resulted in a clinically relevant decrease in HbA1c
and FPG. Surprisingly, despite a marked improvement in
glycaemic control, body weight remained stable during the
treatment period in our study, which supports the argument
that weight gain is not always a complication of insulin
treatment, particularly when using not very high insulin
doses.
The SSED guidelines of 2009 [12], which applied when
the study started, recommended an HbA1c target level of
≤7.0%, and the current SSED guidelines [13] recommend
an individual target level of 6% to 8%, whereas for most
of the patients a value of ≤7.0% is still desirable nowadays.
In our study, 45% of patients achieved an HbA1c level of
≤7.0%. The mean HbA1c level after 6 months treatment
Table 3: Weekly insulin titration schedule based on self-measured
fasting blood glucose (FBG) [15].
Average FBG during the past 2
days
Change in insulin dose (U/day)
≥10 mmol/l 8
7.8–9.9 mmol/l 6
6.7–7.7 mmol/l 4
5.6–6.6 mmol/l 2
4.5–5.5 mmol/l 0
<4.5 mmol/l –2
with insulin glargine was 7.3% ± 1.0% and was similar
across all age groups. A similar response rate was observed
in previous studies [20, 21], whereas response rates
between 60% to 77% were reported elsewhere [15, 22].
Recent studies (ACCORD, ADVANCE und VADT)
[32–34] resulted in the new joint recommendations from
the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD)
[8] with individual aims for HbA1c of higher than <7%
in patients with pre-existing cardiovascular complications,
long duration of diabetes and a history of hypoglycaemia.
During our study these recommendations [8] were not yet
available. The ideal HbA1c range now recommended is
between 6%–7.5% with the lowest complications at an
HbA1c of 6.5% for microvascular and 7% for macrovas-
cular complications. Only for a short diabetes duration
without cardiovascular complications and without frequent
hypoglycaemia is an HbA1c of <7% still recommended.
Aggressive treatment with an HbA1c target of ≤6.5% was
shown to have an increased risk of mortality, probably be-
cause of hypoglycaemia. In our study, the median dura-
tion of diabetes was 6.2 years (and a large proportion of
patients already had cardiovascular disease at the time of
enrolment, suggesting a study population at high risk for
cardiovascular events). We did not analyse individual pa-
tient’s HbA1c targets, but obviously, many physicians chose
a less stringent target in patients with a longer duration
of the disease even before the new recommendations were
published. Otherwise, the proportion of patients in whom
the dose titration was deemed to be completed would have
been higher than 72%.
Limitations of the study
The absence of any further safety information represents
the major limitation of this study, in particular the lack on
hypoglycaemic events. Since this is a prospective observa-
tional study, serious adverse events such as hypoglycaemia
have to be reported directly to Swissmedic Pharmacovigil-
ance centres and can, therefore, not be analysed. One single
report of hypoglycaemia, considered to be non serious was
recorded by a physician as a comment in the CRF. The fact
that no more comments on serious events were reported
in the CRF, could be for various reasons: (a) an indication
that the primary care physicians adopted a less aggressive
and therefore safe titration method, or (b) patients chose
a lower insulin dose than prescribed by the physician or
suggested by the algorithm scheme, as documented by the
low mean insulin dose at the end of follow-up of 28 units,
which corresponds to only nine titration steps by two units,
whereas 26 or 60 steps would have been possible according
to the two different titration algorithms suggested. There
was no systematic monitoring of insulin glargine treatment
during the 6-month observation other than routine clinic-
al visits at baseline and at the end of the study period.
The fact that no reference laboratory was involved and the
participating physicians used their own arrangements for
measuring blood sugar parameters represents a limitation
of the study because of potential differences in measure-
ment methods and bias, but it will most likely not affect
the calculated differences. Since the HbA1c at baseline was
8.9% in the present study, we considered it unethical not
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to give insulin in this group of patients with a long dia-
betes duration. Therefore, the study lacks a direct compar-
ison group. Although we have included more than 300 pa-
tients treated by 72 different physicans from all three major
language regions of Switzerland, further studies in random-
ised populations would be needed before the results can be
applied to the wider type 2 diabetes population in Switzer-
land.
Treatment satisfaction
As in a previous study [22], the vast majority of treating
physicians and patients were satisfied or very satisfied with
the insulin glargine therapy. It is interesting that 80% of pa-
tients chose a disposable pen for initial insulin treatment.
In addition, 99% of patients were satisfied or very satisfied
with use of the SoloSTAR® or ClikSTAR® pens in the
present study. The preference for disposable pens and the
satisfaction underlines the simplicity of education in the
handling of these devices and their acceptance by the pa-
tients.
Whereas randomised comparative trials reflect a method-
ical approach with defined patient populations, systematic
data collection and head-to-head comparisons of treat-
ments, “real life” outcomes generated in observational
studies provide insights into day-to-day medical practice in
unselected patient populations.
In conclusion, treatment with insulin glargine admin-
istered with SoloSTAR® or ClikSTAR® pens and education
on insulin injection with these devices and on self-man-
agement of diabetes was associated with clinically mean-
ingful improvements in HbA1c and fasting plasma glucose
without a mean collective weight gain during a 6-month
study period in patients with type 2 diabetes mellitus, who
has previously failed to reach local targets under OAD
treatment. In primary care practice, this treatment offers
good glycaemic control at a stable body weight, thus con-
tributing to a high satisfaction of both patients and treating
physicians.
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Figures (large format)
Figure 1
Assessment of efficacy (blood glucose control) by physician, evaluation of satisfaction with therapy and device by patients: Proportions of
physicians and patients who were “very satisfied”, “satisfied”, “dissatisfied” or “very dissatisfied” (per protocol population, n = 300).
Figure 2
Weight change in relation to improvement of HbA1c. Correlation of weight change and change in HbA1c, p = 0.01.
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Figure 3
Improvement of HbA1c with the different titration schemes.
A) Physician = titration managed by physician (n = 221), patient = titration managed by patient (n = 91); p = 0.049, adjusted for baseline HbA1c.
B) Improvement of HbA1c in the different titration groups. 1 = change of 2 U every 3 days (n = 58), 2 = weekly adjustment (n = 230), 2 = other
titration scheme (n = 27), p = not significant, adjusted for baseline HbA1c.
C) Titration end not reached (n = 87), Titration end reached (n = 228); p <0.001, adjusted for baseline HbA1c.
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